Keywords :
Bayesian P-splines; Joint models; generalized linear mixed models; longitudinal outcome; survival outcome; Humans; Longitudinal Studies; Proportional Hazards Models; Models, Statistical; Linear Models; Survival Analysis; Glioblastoma/mortality; Computer Simulation; Disease Progression; Bayes Theorem; Glioblastoma; Epidemiology; Statistics and Probability; Health Information Management
Abstract :
[en] In medical studies, repeated measurements of biomarkers and time-to-event data are often collected during the follow-up period. To assess the association between these two outcomes, joint models are frequently considered. The most common approach uses a linear mixed model for the longitudinal part and a proportional hazard model for the survival part. The latter assumes a linear relationship between the survival covariates and the log hazard. In this work, we propose an extension allowing the inclusion of nonlinear covariate effects in the survival model using Bayesian penalized B-splines. Our model is valid for non-Gaussian longitudinal responses since we use a generalized linear mixed model for the longitudinal process. A simulation study shows that our method gives good statistical performance and highlights the importance of taking into account the possible nonlinear effects of certain survival covariates. Data from patients with a first progression of glioblastoma are analysed to illustrate the method.
Funding text :
The authors acknowledge the support of the ARC project IMAL (grant 20/25-107) financed by the Wallonia-Brussels Federation and granted by the Acad\u00E9mie universitaire Louvain. The authors thank the European Organization for Research and Treatment of Cancer for permission to use the data from EORTC-26101. The contents of this publication and methods used are solely the responsibility of the authors and do not necessarily represent the official views of the EORTC. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article.The authors acknowledge the support of the ARC project IMAL (grant 20/25-107) financed by the Wallonia-Brussels Federation and granted by the Acad\u00E9mie universitaire Louvain. The authors thank the European Organization for Research and Treatment of Cancer for permission to use the data from EORTC-26101. The contents of this publication and methods used are solely the responsibility of the authors and do not necessarily represent the official views of the EORTC.
Scopus citations®
without self-citations
0